BioArctic AB (Nasdaq Stockholm: BIOA B) has announced a collaboration and licensing agreement with Novartis Pharma AG (NYSE:NVS) to explore a potential new treatment for neurodegenerative diseases.

The partnership centers around combining BioArctic’s proprietary BrainTransporter technology with a Novartis-owned antibody, aimed